Tuesday, July 1, 2025 7/1/2025

A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma

Award Number: R01AI174540
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/16/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma - PROJECT ABSTRACT Asthma is a heterogenous disease that impacts ~10% of the US population. It presents as a syndrome of non- specific airway hyperresponsiveness, inflammation and intermittent respiratory symptoms. Even though more than half of patients receiving standard asthma medication remain uncontrolled, mainstay treatments have been largely unchanged for several decades. While the introduction of the asthma-specific biologics in the last several years has improved asthma for some, those treatments are extremely costly and are typically reserved for the most severe of patients. For most asthma patients, responses are mediated by environmental allergens which frequently possess potent protease activity. These allergen proteases provoke an increased allergen response, in part by the direct activation of protease-activated receptor-2 (PAR2). PAR2 is a newly established target for development of novel analgesics and therapeutics for inflammatory diseases, including asthma. We have developed novel antagonists to PAR2 that in preliminary experiments using pre-clinical models have proven to be effective in inhibiting or reducing the detrimental physiological changes associated with allergen-induce asthma. Our central hypothesis for this application is: Small molecule pharmacological control of airway epithelial and/or nociceptor PAR2 signaling provides a novel strategy for asthma protection that can be demonstrated in vivo. We propose 3 specific aims, in which we will use a combination of in vitro and in vivo approaches to uncover a mechanistic understanding for the roles for epithelial- and neuronal-expressed PAR2 in allergic asthma. These studies will specify pharmacological impact of PAR2 modulation on airway epithelial cells and sensory neurons in vitro and in pre-clinical asthma models with human validation and will provide mechanistic understanding and cellular targeting for development of novel asthma drugs for clinical trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $759,637 )
2025	2025	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Allergy and Infectious Diseases Research	000	2	5/16/2025	NON-COMPETING CONTINUATION	$759,637
														Subtotal = $759,637

Issue Date FY: 2024 ( Subtotal = $716,690 )
2024	2024	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Allergy and Infectious Diseases Research	000	1	7/16/2024	NEW	$695,740
2024	2024	UNIVERSITY OF ARIZONA	845 N PARK AVE RM 538	TUCSON	AZ	85721	PIMA	USA	Allergy and Infectious Diseases Research	001	1	9/4/2024	NEW	$20,950
														Subtotal = $716,690

Grand Total All Awards = $1,476,327

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma

Award Number: R01AI174540

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/16/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer